Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)


Creative Commons License

Inal A., Kos F. T. , Algin E., Yildiz R., Berk V., Unek I. T. , ...More

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.19, no.2, pp.125-129, 2015 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.5114/wo.2014.43933
  • Title of Journal : WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
  • Page Numbers: pp.125-129

Abstract

Aim of the study: Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for survival in patients with gemcitabine (Gem)-refractory or with gemcitabine and cisplatin (GemCis)-refractory advanced pancreatic cancer.